Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced the Company reached its initial recruitment and
genetic testing milestone in the observational EFRONT Study, being
conducted to advance the genetic understanding of frontotemporal
dementia (FTD).
The EFRONT Study has been conducted with support from Alector, a
clinical-stage biotechnology company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegenerative
diseases, including FTD.
“Screening potential trial participants for genetic variants of
FTD presents significant challenges. CENTOGENE has facilitated
important genetic screening of FTD patients, and we are pleased to
have supported their EFRONT Study,” said Gary Romano, M.D., Ph.D.,
Chief Medical Officer of Alector. “Frontotemporal dementia is a
devastating disease for which new treatment options are urgently
needed. Genetic screening is critical to the successful execution
of clinical trials in genetically defined populations like
FTD-GRN.”
Having met this milestone, CENTOGENE will continue to work with
its extensive network of 30,000 physicians and enroll patients in
the EFRONT Study under its Cento-FTD Program to provide timely
diagnosis and further unlock insights into this neurodegenerative
disorder. Advocacy groups and potential partners are invited to
learn more about this program by contacting efront@centogene.com.
Patients enrolled in the EFRONT Study and identified with
disease-causing mutations may be eligible for participation in
ongoing interventional clinical studies.
“Frontotemporal dementia is a rapidly progressing
neurodegenerative disease, and over recent years, we have made
immense progress in establishing the best diagnostic approaches,”
said Kim Stratton, Chief Executive Officer at CENTOGENE. “In
reaching such a pivotal milestone in our frontotemporal dementia
study, we have been able to unlock significant insights into the
genetic factors – which may enable the development of potentially
life-changing therapeutics for patients around the world.”
“Not only is this milestone a tremendous achievement, but it
also signifies potential that lies ahead,” added Ombretta Palucci,
SVP Real-World Solutions Operations at CENTOGENE. “It forms the
basis of one of the world’s largest FTD registries, which will
enable current and future partners within the Cento-FTD Program to
generate real-world evidence to potentially accelerate treatment
access.”
About Frontotemporal Dementia (FTD)
FTD is a rare neurodegenerative disease and the most common form
of dementia for people under the age of 60. It affects an estimated
50,000 to 60,000 people in the United States and roughly 110,000 in
the European Union. There are multiple heritable forms of FTD,
including FTD-GRN, which is caused by genetic mutations in the
progranulin (GRN) gene. Patients with FTD frequently develop
symptoms such as behavioral changes, lapses in judgment, and
diminished language skills when they are in their 40’s and 50’s,
with the disease running its course in 7-10 years. There are no
FDA-approved treatment options available for any form of FTD.
About the EFRONT Study
The EFRONT Study is a single visit, multi-center,
non-interventional study that investigates the prevalence of
genetic etiologies in frontotemporal dementia (FTD) by genotyping
patients diagnosed with or suspected of FTD.
FTD is a genetically and pathologically heterogeneous
neurodegenerative disease caused by the loss or damage of nerve
cells in the brain’s frontal and temporal lobes. As a result, there
are abnormalities in behavior, personality, and language
comprehension problems, like lack of interest, judgment, loss of
empathy, and apathy.
To learn more about how you can enroll in the EFRONT Study,
visit ClinicalTrials.gov.
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
800,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 285 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “potential,” “predict,” “objective” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth, execute our
business strategy and enter into new client relationships, our
dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our continued ongoing compliance with
covenants linked to financial instruments, our requirement for
additional financing, and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on May 16, 2023,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
CONTACT
CENTOGENE
Melissa HallCorporate Communications Press@centogene.com
Lennart StreibelInvestor Relations IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2024 to May 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From May 2023 to May 2024